If you are not happy with the results below please do another search
Under the agreement, Dr. Reddy’s gets exclusive commercialization rights in the United States as well as semi-exclusive rights in Europe and United Kingdom, and Alvotech will be responsible for development and manufacture of the product.
Carlos Dortrait, senior vice president & general manager of U.S. Immunology & Neuroscience at Bristol Myers Squibb, explains the importance of empowering patients and giving them the confidence to speak with doctors so they can seek the treatment they need, in this case for treating plaque psoriasis. Actress, writer, and producer Mindy Kaling recently joined actor Ted Danson in the BMS “SO, Have You Found It?” campaign (with their video slated to be released soon), which aims to strengthen the voices of U.S. patients living with the condition. Danson has been living with plaque psoriasis for many years and Kaling, who does not have psoriasis, has the role of patient empowerment through self advocacy.
“In a rapidly changing healthcare landscape, new policies combined with significant cost pressures and evolving business models continue to impact drug access and potentially increase restrictions,” said Kim Wishnow-Per, President, MHMM. “We created these proprietary solutions following conversations with our client partners and listening to their specific needs. By designing these three offerings to help solve for their challenges, we are excited to bring new value to our clients and their customers.”
The British-Swedish company on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.
The entrepreneur and life sciences industry veteran joins the agency as president, a newly created position.
Med Ad News caught up with Bauman ahead of the agency’s announcement, and he was clear in his enthusiasm not only for imre’s creative legacy but also the agency’s culture and people, many of whom Bauman has worked with or known professionally throughout his career. “We’re putting the band back together. Anna [Kotis, imre president] and I have a long-time partnership, going almost 20 years back to when we were partners. Scott Tucker [imre’s chief client officer] and I also worked together.”
The regulator approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.
“We want to introduce Precision AQ as a team of advisors, experts, and creators to sit in the room with our clients to partner, looking at access as a continuum,” President Doug Fulling told Med Ad News. “This has been 10 years in the making. We started the rebrand process six months ago, but the reason that we’re doing this now is we want to simplify our North Star and where we’re going in the marketplace.”
The Boston-based drug developer will use its proprietary technology along with Lilly’s expertise in oncology drugs to develop therapies for a range of solid tumors.
Today the company announced that its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.